Kimberly Self
Family Medicine · Arab, ALNPI 1932619236
Payments from drug & device makers
Across 399 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$798
- AstraZeneca$539
- Lilly USA, LLC$377
- Pfizer$300
- Novo Nordisk$271
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,19899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,283 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $92,287 |
| MounjaroTirzepatide | 50 | $74,305 |
| JardianceEmpagliflozin | 52 | $55,725 |
| TrulicityDulaglutide | 37 | $46,438 |
| OzempicSemaglutide | 30 | $38,140 |
| RybelsusSemaglutide | 11 | $27,047 |
| LinzessLinaclotide | 31 | $24,652 |
| FarxigaDapagliflozin Propanediol | 22 | $22,326 |
| MyrbetriqMirabegron | 33 | $22,025 |
| VraylarCariprazine Hcl | 14 | $20,697 |
| JanuviaSitagliptin Phosphate | 15 | $16,248 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $13,692 |
| EliquisApixaban | 11 | $12,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $11,389 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $377 | $120,74387 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $798 | $109,792120 claims |
| Novo NordiskOzempic, Rybelsus | $271 | $65,18641 claims |
| Boehringer IngelheimJardiance, Tradjenta | $91 | $61,53963 claims |
| AbbVieLinzess, Vraylar, Synthroid | $1,670 | $47,17562 claims |
| AstraZenecaFarxiga, Symbicort | $539 | $28,43136 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $22,02533 claims |
| MerckJanuvia | $37 | $16,24815 claims |
| PfizerEliquis | $300 | $12,03911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Arab
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.